The androgen receptor (AR) is a validated target for the prevention and treatment of prostate cancer (PCa), and androgen deprivation via pharmaceutical treatment induces remission of the primary form of PCa (Scher & Sawyers, 2005). This evidence concerns the gene AR and prostate carcinoma.